Cite
MLA Citation
Sophie Postel-Vinay et al.. “First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).” Journal for immunotherapy of cancer, vol. 11, no. 3, 2023, p. . http://access.bl.uk/ark:/81055/vdc_100180908824.0x000008